Aptus Pharma Delivers Strong H1 FY27 Growth with Expansion Roadmap
Aptus Pharma Ltd · Investor Presentation · 23 Oct 2026, 11:01 pm
Aptus Pharma Delivers Strong H1 FY27 Growth with Expansion Roadmap Aptus Pharma reported robust financial results for the half year ended 30th Sep'26, with revenue from operations surging nearly twofold YoY to ₹48.92 crore, compared to ₹14.38 crore in H1 FY26. EBITDA stood at ₹7.68 crore, while net profit reached ₹5.08 crore against ₹1.75 crore in the previous year period. Acute therapy contributed ~44% of sales, followed by chronic (~20%) and wellness/OTC (~20%). Strategically, the company plans 46% geographic coverage by Mar'27, 20% in-house manufacturing by Mar'28, and a pan-India footprint by Mar'29.
Original exchange filing (PDF)
More announcements from Aptus Pharma Ltd
- Outcome of Board Meeting - Allotment of Equity Shares on Preferential Basis under Regulation 30 of SEBI LODR Regulations, 2015 · 12 Nov 2026
- Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting for .... · 06 Nov 2026
- Receipt of In-Principle Approval for Preferential Issue · 31 Oct 2026
- Transcript for Earning Call for the Quarter and Half Year ended on September 30, 2026 · 30 Oct 2026
- Audio recording of the Earnings Call dated October 26, 2026 · 27 Oct 2026
- Intimation of Earnings Call for the quarter and half year ended September 30, 2026 · 26 Oct 2026
- Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company .... · 21 Oct 2026
- Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company .... · 21 Oct 2026
